Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.
“We do look at immunology as being very, very attractive, and in certain areas, there’s so much unmet medical need,” Jennifer Taubert, executive vice president and worldwide pharma chairman, said Monday during a fireside chat at the J.P. Morgan Healthcare Conference.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,